This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Paul, M. Articles by Jabbar, M. A. Search for Related Content PubMed PubMed Citation Articles by Paul, M. Articles by Jabbar, M. A.

 Previous Article  |  Next Article 

J Virol, February 1998, p. 1270-1279, Vol. 72, No. 2
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Mutational Analysis of the Human Immunodeficiency Virus Type 1 Vpu Transmembrane Domain That Promotes the Enhanced Release of Virus-Like Particles from the Plasma Membrane of Mammalian Cells

Mousumi Paul, Suparna Mazumder, Nicholas Raja, and M. Abdul Jabbar^*

Department of Molecular Biology, The Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio 44195

Received 22 August 1997/Accepted 24 October 1997

Human immunodeficiency virus type 1 Vpu is a multifunctional phosphoprotein composed of the N-terminal transmembrane (VpuTM) and C-terminal cytoplasmic domains. Each of these domains regulates a distinct function of the protein; the transmembrane domain is critical in virus release, and phosphorylation of the cytoplasmic domain is necessary for CD4 proteolysis. We carried our experiments to identify amino acids in the VpuTM domain that are important in the process of virus-like particle (VLP) release from HeLa cells. VLPs are released from the plasma membrane of HeLa cells at constitutive levels, and Vpu expression enhanced the release of VLPs by a factor of 10 to 15. Deletion of two to five amino acids from both N- and C-terminal ends or the middle of the VpuTM domain generated mutant Vpu proteins that have lost the ability to enhance VLP release. These deletion mutants have not lost the ability to associate with the wild-type or mutant Vpu proteins and formed complexes with equal efficiency. They were also transported normally to the Golgi complex. Furthermore, a Vpu protein having the CD4 transmembrane and Vpu cytoplasmic domains was completely inactive, and Vpu proteins harboring hybrid Vpu-CD4 TM domains were also defective in the ability to enhance the release of VLPs. When tested for functional complementation in cotransfected cells, two inactive proteins were not able to reconstitute Vpu activity that enhances the release of Gag particles. Coexpression of functional CD4/Vpu hybrids or wild-type Vpu with inactive mutant CD4/Vpu proteins revealed that mutations in the VpuTM domain could dominantly interfere with Vpu activity in Gag release. Taken together, these results demonstrated that the structural integrity of the VpuTM domain is critical for Vpu activity in the release of VLPs from the plasma membrane of mammalian cells.

---

^* Corresponding author. Present address: Department of Microbiology and Immunology, Emory Vaccine Research Center, Emory University School of Medicine, G 211 Rollins Research Bldg., Atlanta, GA 30322. Fax: (404) 727-3722.

This article has been cited by other articles:

• Noble, B., Abada, P., Nunez-Iglesias, J., Cannon, P. M. (2006). Recruitment of the Adaptor Protein 2 Complex by the Human Immunodeficiency Virus Type 2 Envelope Protein Is Necessary for High Levels of Virus Release. J. Virol. 80: 2924-2932 [Abstract] [Full Text]  
• Abada, P., Noble, B., Cannon, P. M. (2005). Functional Domains within the Human Immunodeficiency Virus Type 2 Envelope Protein Required To Enhance Virus Production. J. Virol. 79: 3627-3638 [Abstract] [Full Text]  
• Ewart, G. D., Nasr, N., Naif, H., Cox, G. B., Cunningham, A. L., Gage, P. W. (2004). Potential New Anti-Human Immunodeficiency Virus Type 1 Compounds Depress Virus Replication in Cultured Human Macrophages. Antimicrob. Agents Chemother. 48: 2325-2330 [Abstract] [Full Text]  
• Nayak, B. P., Sailaja, G., Jabbar, A. M. (2003). Enhancement of gp120-Specific Immune Responses by Genetic Vaccination with the Human Immunodeficiency Virus Type 1 Envelope Gene Fused to the Gene Coding for Soluble CTLA4. J. Virol. 77: 10850-10861 [Abstract] [Full Text]  
• Komoto, S., Tsuji, S., Ibrahim, M. S., Li, Y.-G., Warachit, J., Taniguchi, K., Ikuta, K. (2003). The Vpu Protein of Human Immunodeficiency Virus Type 1 Plays a Protective Role against Virus-Induced Apoptosis in Primary CD4+ T Lymphocytes. J. Virol. 77: 10304-10313 [Abstract] [Full Text]  
• Barlow, K. L., Ajao, A. O., Clewley, J. P. (2003). Characterization of a Novel Simian Immunodeficiency Virus (SIVmonNG1) Genome Sequence from a Mona Monkey (Cercopithecus mona). J. Virol. 77: 6879-6888 [Abstract] [Full Text]  
• Sailaja, G., Husain, S., Nayak, B. P., Jabbar, A. M. (2003). Long-Term Maintenance of gp120-Specific Immune Responses by Genetic Vaccination with the HIV-1 Envelope Genes Linked to the Gene Encoding Flt-3 Ligand. J. Immunol. 170: 2496-2507 [Abstract] [Full Text]  
• Akari, H., Bour, S., Kao, S., Adachi, A., Strebel, K. (2001). The Human Immunodeficiency Virus Type 1 Accessory Protein Vpu Induces Apoptosis by Suppressing the Nuclear Factor {kappa}B-dependent Expression of Antiapoptotic Factors. JEM 194: 1299-1312 [Abstract] [Full Text]  
• Bour, S., Perrin, C., Strebel, K. (1999). Cell Surface CD4 Inhibits HIV-1 Particle Release by Interfering with Vpu Activity. J. Biol. Chem. 274: 33800-33806 [Abstract] [Full Text]  
• Bour, S., Perrin, C., Akari, H., Strebel, K. (2001). The Human Immunodeficiency Virus Type 1 Vpu Protein Inhibits NF-kappa B Activation by Interfering with beta TrCP-mediated Degradation of Ikappa B. J. Biol. Chem. 276: 15920-15928 [Abstract] [Full Text]